Clover Health Investments, Corp.

Clover Health Investments, Corp.

4.95
USD
-0.01
(-0.20%)
-0.03EPS
2.77BMarket Cap
Mar 04Next Earn
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.14
1.66
3.13
2.3
2.61
2.8
3.76
- -
Basic EPS, GAAP
-0.9
-0.34
-1.25
-0.71
-0.44
-0.09
-0.17
- -
Free Cash Flow per Basic Share
-0.4
-0.29
-0.6
-0.44
-0.3
0.07
-0.13
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
-1.53
1.14
0.75
0.59
0.68
0.59
- -
Tangible Book Value per Share
- -
-1.54
1.13
0.7
0.58
0.67
0.59
- -
Basic Weighted Avg Shares
404
404
471
476
482
490
512
524
Sales/Revenue/Turnover
462
673
1,472
1,097
1,261
1,371
1,924
- -
Operating Margin (%)
-39.63
-13.78
-43.27
-26.14
-14.24
-3.32
-4.44
- -
Depreciation Expense
1
1
1
1
3
1
2
- -
Net Income, GAAP
-364
-136
-588
-340
-213
-43
-86
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-78.69
-20.27
-39.93
-30.97
-16.93
-3.14
-4.45
- -
Working Capital
- -
26
380
193
167
130
99
- -
LT Debt
- -
113
25
4
3
- -
- -
- -
Total Equity
- -
-613
539
357
286
341
309
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
-76.11
-66.34
-13.71
-26.33
- -

Capital Structure

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
525
529
402
Market Capitalization
924
2,773
1,732

Working Capital

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
448
485
- -
Cash, Cash Equivalents & STI
204
243
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
337
323
- -
Payables & Accruals
331
317
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-46.38%
-9.51%
Free Cash Flow
- -
-69.87%
-307.21%
Net Income, GAAP
- -
54.12%
98.91%
Sales/Revenue/Turnover
- -
31.46%
40.34%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
347
356
331
337
1,371
2025
462
478
497
488
1,924
2026
749
743
- -
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.04
0.02
-0.02
-0.04
-0.09
2025
- -
-0.02
-0.05
-0.1
-0.17
2026
0.05
0.05
- -
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
Andrew Toy
Full Time Employees
724
Sector
Finance
Industry
Life/Health insurance
Address
1209 Orange Street Wilmington DE United States 19801
IPO Date
Jun 12, 2020
Business
Clover Health Investments, Corp. is a healthcare technology company primarily focused on providing Medicare Advantage insurance plans combined with a proprietary software platform designed to improve clinical outcomes and reduce healthcare costs. The company offers a comprehensive suite of insurance products including Preferred Provider Organization (PPO) and Health Maintenance Organization (HMO) plans targeting Medicare-eligible seniors, with a differentiated focus on wide-network, high-choice PPO plans. Clover Health’s flagship software, Clover Assistant, integrates patient data from over 100 sources using artificial intelligence, natural language processing, and machine learning to empower physicians in proactive chronic disease management and enhance quality of care. The company also extends its technology through its subsidiary Counterpart Health, which licenses its AI-driven platform to third-party healthcare providers. Founded in 2014 and headquartered in Wilmington, Delaware, Clover Health operates Medicare Advantage plans in five states, serving over 100,000 members with coverage spanning 203 counties, including plans with $0 to low monthly premiums and additional benefits such as dental, vision, hearing, and over-the-counter drug coverage. The company’s insurance segment generates revenues through Medicare contracts, while its technology platform aims to improve physician efficiency and patient health outcomes. Clover Health stands out with its AI-powered HEDIS flywheel, which has driven it to become the top-performing PPO plan by clinical quality measures. Recent major developments include the launch of the 2026 Medicare Advantage portfolio with a stable or improved plan lineup accessible to 5.2 million Medicare beneficiaries, emphasizing broader PPO coverage and AI-supported care through Clover Assistant. The company reported significant growth in 2025, with Medicare Advantage membership up 35% year-over-year, total revenues increasing 50%, and a move toward profitability with adjusted EBITDA improving notably. Clover Health also raised its full-year 2025 guidance, highlighting expectations for continued membership growth, expanded adjusted EBITDA profitability through 2027, and a favorable regulatory environment in Medicare Advantage. Additionally, the company made its AI platform available to third-party partners on October 14, 2025, advancing its strategic shift toward scaling technology beyond insurance offerings. Clover Health went public in early 2021 through a merger with Social Capital Hedosophia Holdings Corp. III and continues to focus on healthcare equity for seniors, extending access to affordable, comprehensive Medicare plans. It combines health insurance with advanced data-driven technology solutions to enhance care quality and reduce medical costs, positioning itself as both a health insurer and a healthcare technology innovator within the Medicare Advantage market. The company is committed to expanding its technology-enabled healthcare services and participating in the evolving value-based care landscape. This profile reflects Clover Health Investments Corp.'s current operations, product offerings, and strategic developments as of late 2025.

Company News

  • Clover Health Investments Sees 2027 Growth as Rival Exits New Jersey

  • Clover Health Investments, Corp. (CLOV) Presents at 2026 UBS Global Healthcare Conference Transcript

  • Clover Health's Best Earnings Years May Still Be Ahead

  • Clover Health Investments, Corp. (CLOV) Q3 2026 Earnings Call Transcript

  • What Clover Health Investments (CLOV) Said on Its Q3 Earnings Call

  • Clover Health Reports Third Quarter 2026 Results

  • Clover Health to Participate in Upcoming UBS Global Healthcare Conference

  • Clover Health Investments (NASDAQ:CLOV) Insider Karen Soares Sells 14,673 Shares of Company Stock

  • Clover Health Investments (NASDAQ:CLOV) CEO Andrew Toy Sells 62,176 Shares of Stock

  • Clover Health Investments (NASDAQ:CLOV) CEO Conrad Wai Sells 23,627 Shares of Stock

  • Clover Health Earns Top Honors in U.S. News & World Report's 2027 Medicare Advantage Ratings Across Three States

  • Clover Health Medicare Advantage PPO Plans Earn 5 Star Rating for 2027

  • At 67, He’ll Keep His Clover Medicare Advantage Plan for 2027. The Premium Will Stay $0. The Most He Can Be Billed Will Jump $1,144

  • Clover Health to Report Third Quarter 2026 Financial Results on November 4, 2026

  • Clover Health's 2027 Medicare Advantage Plans Emphasize PPO Choice, Preventive Care and Member Value

  • UPDATE – Clover Health Welcomes Former U.S. Senator Robert Torricelli and Dr. Brian J. Miller M.D.

  • Clover Health Welcomes Former U.S. Senator Robert Torricelli and MedPAC Commissioner Dr. Brian J. Miller M.D.

  • Clover Health Sees PPO Edge, Cohort Gains as Medicare Advantage Pricing Tightens

  • Tidal Investments LLC Takes $2.16 Million Position in Clover Health Investments, Corp. $CLOV

  • Clover Health Investments (NASDAQ:CLOV) Stock Price Down 6.5% Following Insider Selling